Bordetella pertussis fimbriae 2/3 antigen is a vaccine for the prophylaxis of the disease caused by Bordetella pertussis which is a a Gram-negative coccobacillus that expresses two serologically distinct fimbriae...
- First approval
- Canada, 2005 · United States, 2002 · European Union, 2021
- Also known as
- Bordetella pertussis fimbriae 2/3 vaccine, inactivated
- Brand names
Resolves to
Compound
Clinical / RWD
What you can answer from here — as of April 02, 2025
Which companies are running trials of Bordetella pertussis fimbriae 2/3 antigen, in which indications and phases, and which of those programs are still active?
Create a free account or log in to explore the full data card.
Create Account